Appendix B. Study Questions: Refinement by Experts

Sherita Golden; L Ebony Boulware; Gail Berkenblit; Frederick L Brancati; Geetanjali Chander; Spyridon Marinopoulos; Michael Paasche-Orlow; Neil Powe; Tejal Rami

This publication is provided for historical reference only and the information may be out of date.

Appendix B. Study Questions: Refinement by Experts

Feedback Form for Question Refinement

Evidence Report on the Use of Glycohemoglobin and Microalbuminuria in Diagnosis and Monitoring of Diabetes Mellitus Johns Hopkins Evidence-based Practice Center

Name: <<NAME>>

Below is a non-prioritized list of research questions to be considered for inclusion in the evidence report. For each question, please circle your response for the following:
1. Rank the question to indicate what you feel is the priority/clinical importance of the question.
2. Indicate your sense of the ability to answer the question, yes (there is appropriate evidence available to address this question) or no (there is no appropriate evidence to address this question)
3. Indicate the clarity of the wording of the questions, yes (question clear and complete) or no (question is unclear or incomplete). If no, please indicate in space provided the problem with the wording and/or suggestion for alternative wording.
  Please provide comments on each question.

Please fax back completed form no later than 5 p.m. Friday January 4, 2002

(Attention: Dr. Sherita Golden).

Table

Δ GFR CVD

Are there other important, answerable questions we have not included that should be addressed in the evidence report? Please write question(s) below.

Thank you for your guidance in the essential task of refining the questions for the evidence report.

Please contact Tejal Rami or Dr. Sherita Golden.

Please fax back completed form no later than 5 p.m. Friday January 4, 2002.

(Attention: Dr. Sherita Golden).

Publication Details

Copyright

Publisher

Agency for Healthcare Research and Quality (US), Rockville (MD)

NLM Citation

Golden S, Boulware LE, Berkenblit G, et al. Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus. Rockville (MD): Agency for Healthcare Research and Quality (US); 2003 Oct. (Evidence Reports/Technology Assessments, No. 84.) Appendix B. Study Questions: Refinement by Experts.

Glycohemoglobin Questions	Ranking of question					Answerable?		Clear wording?
What is the relationship between HbA1c and microvascular diabetic complications (retinopathy, nephropathy, neuropathy)?	1	2	3	4	5	Y	N	Y	N

Comments. For example, if question is not clear, please describe problem or suggest alternative wording.

What is the relationship between HbA1c and macrovascular diabetic complications (CVD, peripheral vascular disease)?	1	2	3	4	5	Y	N	Y	N

Comments. For example, if question is not clear, please describe problem or suggest alternative wording.

What is the shape of the relationship between HbA1c and diabetic complications in various ranges of HbA1c, particularly at levels of HbA1c below 7%?	1	2	3	4	5	Y	N	Y	N

Comments. For example, if question is not clear, please describe problem or suggest alternative wording.

What is the effect of diabetic treatment on the relationship between HbA1c and microvascular / macrovascular complications?	1	2	3	4	5	Y	N	Y	N

Comments. For example, if question is not clear, please describe problem or suggest alternative wording.

Do differences in the methodologies of measuring glycohemoglobin warrant standardization of methodology?	1	2	3	4	5	Y	N	Y	N

Comments. For example, if question is not clear, please describe problem or suggest alternative wording.

Microalbuminuria Questions	Ranking of question						Answerable?		Clear wording?
Do various tests for measuring microalbuminuria (i.e. dipstick testing for microalbuminuria and albumin:creatinine ratio (both random and timed) correlate?	1	2	3	4	5	6	Y	N	Y	N

Comments. For example, if question is not clear, please describe problem or suggest alternative wording.

Are the various tests for microalbuminuria predictive of Δ GFR CVD CVD mortality All cause mortality	1	2	3	4	5	6	Y	N	Y	N

Comments. For example, if question is not clear, please describe problem or suggest alternative wording.

What is the risk relationship between microalbuminuria and Δ GFR CVD CVD mortality All cause mortality	1	2	3	4	5	6	Y	N	Y	N

Comments. For example, if question is not clear, please describe problem or suggest alternative wording.

Do the risk relationships between proteinuria and clinical complications allow selection of an optimal cut point for defining microalbuminuria?	1	2	3	4	5	6	Y	N	Y	N

Comments. For example, if question is not clear, please describe problem or suggest alternative wording.

How does treatment of microalbuminuria affect the relationship between microalbuminuria and the risk of Δ GFR CVD CVD mortality All cause mortality	1	2	3	4	5	6	Y	N	Y	N

Comments. For example, if question is not clear, please describe problem or suggest alternative wording.

How often should microalbuminuria be monitored to confirm a diagnosis?	1	2	3	4	5	6	Y	N	Y	N

Comments. For example, if question is not clear, please describe problem or suggest alternative wording.